Press Release

MONTREAL, Oct 10, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that its late breaking abstract describing the preliminary follow-up data from the ongoing REP 401 clinical trial has been accepted as a late-breaking presentation at the 2017 meeting of the American Association for the Study of Liver Disease (AASLD) to be held October 20-24, 2017 in Washington, DC, U.S.A.,

The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of Replicor’s lead HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in patients with chronic HBeAg negative HBV infection.

Replicor’s late breaking poster presentation (LB-24) to be presented on October 23, 2017 will demonstrate that control of HBV infection (HBsAg, anti-HBs and HBV DNA) and normalization of liver function is currently persisting for up to 24 weeks after withdrawal of all therapy in experimental patients who have completed 48 weeks of triple combination therapy.

Replicor will also be presenting two additional regular poster presentations (Abstracts 924 and 942) on October 21, 2017 which will provide updates on the mechanisms of action of REP 2139 in HBV and HDV infection.

These presentations will expand on the existing clinical data already demonstrating the unique ability of NAP-based combination therapy to eliminate serum HBsAg in most patients and to achieve functional cure in patients with HBV and HBV / HDV co-infection.

Replicor’s presentations from AASLD 2017 will be available on the company’s website following their disclosure at the meeting at For further information about the 2017 AASLD Meeting visit:

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at

Media Contact:
Natacha Dorget
(514) 733-1998